Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Annovis Bio, Inc. Common Stock (NY:ANVS)

4.460 +0.160 (+3.72%)
Official Closing Price Updated: 7:00 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate
Via Investor Brand Network
News headline image
Annovis Announces New Publication in a Peer-Reviewed Journal
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
News headline image
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
From Annovis Bio
Via Business Wire
News headline image
Annovis Bio Announces Pricing of $7.5 Million Public Offering
From Annovis Bio, Inc.
Via Business Wire
News headline image
Annovis Bio Announces Launch of Proposed Public Offering
From Annovis Bio, Inc.
Via Business Wire
News headline image
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
From Annovis Bio, Inc.
Via Business Wire
News headline image
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
From Annovis Bio, Inc.
Via Business Wire
News headline image
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Annovis Bio, Inc.
Via Business Wire
News headline image
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
From Annovis Bio, Inc.
Via Business Wire
News headline image
Annovis Bio Announces the Filing of a Groundbreaking Patent
From Annovis Bio, Inc.
Via Business Wire
News headline image
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
From Annovis Bio, Inc.
Via Business Wire
News headline image
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
News headline image
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
News headline image
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
News headline image
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.